Lexology July 13, 2022
Goodwin Procter LLP

On July 6, 2022, Katherine Vidal, the Undersecretary of Commerce for Intellectual Property and Director of the USPTO, published her response to the letter sent by Janet Woodcock (former acting FDA Commissioner) to the former Director of the USPTO, Andrew Hirshfield. Concurrently, Director Vidal and Commissioner Califf published a blog post summarizing the steps the Biden Administration is taking to promote competition and lower drug prices. We previously posted on the original Woodcock letter.

As a reminder, the letter from Commissioner Woodcock was sent to Director Hirshfield pursuant to Executive Order 14036 (Executive Order on Promoting Competition in the American Economy | The White House), which focused on promoting competition in the American economy, including with respect to pharmaceuticals. With...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, FDA, Govt Agencies, Healthcare System, Pharma, Pharma / Biotech, Pricing / Spending
Healthcare prices surge 14% in last 5 years: Report
What Fishing Can Teach Us About Lowering Healthcare Costs
Drug Expenditures Surge. Drug Prices Don't.
Weight-Loss Drugs Drive U.S. Prescription Spending
Why Are Cash Prices Lower Than Health Insurance Negotiated Prices?

Share This Article